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Purpose/Objective: Intensity modulated radiotherapy (IMRT) is an 
alternative to improve dose homogeneity within the breast and to 
enhance coverage of complex target volumes, especially for selected 
patients whom level I axillary radiation therapy is required. To 
determine an optimal IMRT method of targeting breast within regional 
nodes included axillary nodes (level I to III), in selected breast cancer 
patients and to demonstrate the clinical feasibility. 
Materials and Methods: Patients were simulated in supine position 
with a CT scan performed without gating. Clinical targets volumes 
included breast, axillary lymph nodes (level I and III axilla, 
supraclavicular fossa) and internal mammary nodes (IMN). The 
prescribed dose was 50 Gy in 25 fractions to these target volumes with 
a boost of 16 or 20 Gy respectively to tumor bed or tumor. Boost was 
treated with traditional 3DCRT. Consequently, a technique with fixed 
fields IMRT (5 à 6 fields) was used. Optimization structures were 
created with an isotropic margin of 5mm from the target volumes, 
except in the anterior axis where PTV is reduce of 5 mm under the 
skin. To take into account inter and intra fraction motions, a 
dosimetric artifice was necessary: due to artificial addition of tissue 
on CT is not representative of the real condition of treatment, we use 
a brush tool© (Varian) in order to deliver the same dose level by 
sequencing the mobile part of the breast in the air. The homogeneity 
index (HI) defined as (Dmax - Dmin)/Dprescribe) was calculated for all 
targets. A systematic quality control of each field analyzing both point 
dose and dose-distribution map was done on an Archeck© device. A 
specific image-guided radiotherapy (IGRT) procedure was daily 
performed using kilovoltage x-ray imaging for patient positioning and 
megavoltage x-ray-imaging for 'secure' field position. Acute toxicities 
were assessed using the CTCAE v4.0 scale. 
Results: De to 3DCRT plan considered not conform, four patients 
require this IMRT technic included 2 patients with left breast cancer. 
Three patients were treated with exclusive radiation therapy without 
surgery and one patient had massive pathologic involved axillary 
nodes. Median age was 68 years (range 58-84). Dosimetric data are 
presented in table 1. The results of HI demonstrate a good 
homogeneity to target nodes. The IMRT plans achieved no degradation 
of breast coverage but give higher contralateral breast dose, 
ipsilateral lung V5 and heart V5 than traditional 3DCRT plans. No 
grade 3-4 acute toxicity was observed during treatment. 
  
Conclusions: Indications for breast IMRT should be personalized and 
selected. Fixed field IMRT with 5-6 fields with adding brush for 
sequencing and irradiation at the same dose level in the mobile part 
of the breast could be an alternative to gating and arc therapy. 
Contralateral breast dose should be considered take into account 
radiation-induced second cancer risk.  
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Purpose/Objective: At presence, more and more younger patients 
(pts) suffer from prostate cancer. The conventional intensity-
modulated radiation therapy (IMRT) is a standard technique for 
prostate cancer treatment. The aim of this study was to investigate 
the dose received in organ at risk – testes – during step-and-shoot 
IMRT delivery and X-ray volume imaging (XVI) for position verification 
in localized prostate cancer pts.  
Materials and Methods: Datasets of 15 localized prostate cancer pts 
who received the mean total dose of 75Gy to the prostate using 6-MV 
and 15-MV photon beams were evaluated. Oncentra Masterplan 
treatment planning system (Collapsed Cone algorithm) was used to 
calculate testes dose from small field step-and-shoot IMRT. The dose 
from repeated XVI performed during 1st, 2nd, 3rd and every 7th 
fractions of radiotherapy was measured using diagnostic dosemeter 
DIADOS E (PTW) with semiconductor detector. Mean volumes of PTV 
and testes were 223,1 cm3 and 57,2 cm3, respectively.  
Results: A mean dose of 178 cGy to the testes was delivered during 
IMRT. Dose distribution comparisons between 6-MV and 15-MV photon 
beams were not significantly different although a trend for lower 
mean testicular dose delivered with 6-MV energy, than with 15-MV 
beams was observed (140 vs 180 cGy, respectively). The strong 
correlation between the mean testicular dose and the volume of PTV 
was observed (r = 0,9 for 6-MV and r = 0,6 for 15-MV). The detected 
testicular mean dose was 7,5 mGy from one XVI scan, whereas from 
all sessions of XVI verification – 73,3 mGy, with mean XVI numbers – 
10. The lowest dose for testes was for 10cm-sized XVI field. The 
testes-out-of-field and in-field scatter dose was 4,36 mGy and 6,8 
mGy, respectively.  
Conclusions: Dose to the testes from prostate step-and-shoot IMRT is 
significant in aspect of sterilization and can be minimized by choosing 
6 MV photon energies, as well as by using the smallest portal sizes 
necessary for image guidance. 
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Purpose/Objective: A selection of proper energy in treatment 
planning is very important because of having different dose 
distribution in body as photon energy. In generally, the low energy 
photon has been used in intensity-modulated radiation therapy (IMRT) 
for head and neck (H&N) cancer. The aim of this study was to 
evaluate the effect of partially used high energy photon at posterior 
oblique fields on IMRT plan for H&N cancer. 
Materials and Methods: The study was carried out on 10 patients 
(nasopharyngeal cancer 5, tonsilar cancer 5) treated with IMRT in 
Seoul-National University Bundang Hospital. CT images were acquired 
3 mm of thickness in the same condition and the treatment plan was 
performed by Eclipse (Ver.7.1, Varian, Palo Alto, USA). Two plans 
were generated under same planing objectives, dose volume 
constraints, and eight fields setting : (1) The low energy plan (LEP) 
created using 6 MV beam alone, (2) the partially used high energy plan 
(PHEP) created partially using 15 MV beam at two posterior oblique 
fields with deeper penetration depths, while 6 MV beam was used at 
the rest of fields. The plans for LEP and PHEP were compared in terms 
of coverage, conformity index (CI) and homogeneity index (HI) for 
planning target volume (PTV). For organs at risk (OARs), Dmean and D50% 
were analyzed on both parotid glands and Dmax, D1% for spinal cord 
were analyzed. Integral dose (ID) and total monitor unit (MU) were 
compared as addition parameters. For the comparing dose to normal 
tissue of posterior neck, the posterior-normal tissue volume (P-NTV) 
was set on the patients respectively. The Dmean, V20Gy and V25Gy for P-
NTV were evaluated by using dose volume histogram (DVH). 
Results: The dose distributions were similar with regard to coverage, 
CI and HI for PTV between the LEP and PHEP. No evident difference 
was observed in the spinal cord. However, the Dmean, D50% for both 
parotid gland were slightly reduced by 0.6%, 0.7% in PHEP. The ID was 
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reduced by 1.1% in PHEP, and total MU for PHEP was 1.8% lower than 
that for LEP. In the P-NTV, the Dmean, V20Gy and V25Gy of the PHEP were 
1.6%, 1.8% and 2.9% lower than those of LEP. 
Conclusions: Dose to some OARs and a normal tissue, total monitor 
unit were reduced in IMRT plan with partially used high ergy photon. 
Although these reduction are unclear how have a clinical benefit to 
patient, application of the partially used high energy photon could 
improve the overall plan quality of IMRT for head and neck cancer. 
   
PO-0935   
IMRT treatment for palliative irradiation of spinal bone metastasis 
I. Kant1, M. Spoolder1, E. Loeters1, A. Minken1, C. Niël1 
1RISO, Radiotherapy, Deventer, The Netherlands  
 
Purpose/Objective: To assess the practical feasibility of IMRT 
treatment planning and delivery for single dose palliative radiotherapy 
in spinal bone metastases limiting adverse effects as vomiting, nausea 
and diarrhea. 
Materials and Methods: Target volumes and critical structureswere 
delineated. IMRT plans were created using RayStation (RaySearch, 
Stockholm) for 36 patients previously treated with one posterior field. 
The plans consisted of three beams with in total 9 segments at fixed 
gantry anglesof 130, 180 and 230 degrees using 6 MV photons. IMRT 
plans were compared to the conventional plans with respect to 
planning time and treatment time. Normal tissue sparing as well as 
target coverage and dose homogeneity were evaluated by dose 
volume histograms. 
Results: IMRT plans resulted in normal tissue sparing resulted from 
IMRT due to a more localized dose delivery. Dose to the kidneys was 
higher in IMRT patients, but to a level well below the QUANTEC-
tolerance limits. IMRT treatment planning results in improved target 
homogeneity.  
In the higher regionsof the spine (Th4-Th9) the esophagus still 
receives a high amount of dose.  
 
  
 
 Conclusions: Implementation of IMRT in palliative treatment of spinal 
metastases using 1x8Gy is feasible without a significant increase of 
labor or treatment time. It decreases the amount of dose in normal 
tissue that might result in acute adverse effects. The findings in this 
study should be tested to show the clinical value of lowering the dose 
in normal tissue. Other bundle designs might be investigated to lower 
the esophageal dose. Implementation of IMRT treatment planning and 
delivery thereby seems feasible in clinical practice. 
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Purpose/Objective: the primary aim to conduct a dosimetric study 
between WP-3D-CRT and WP-IMRT as regard to coverage to target 
volumes and doses to risk structures for definitive treatment of 
cervical cancer stage IB-IVA. 
Materials and Methods: 15 patients with cervical cancer stage IB-IVA 
were treated with WP-3D CRT (45Gy/25 fr/5weeks) with concomitant 
weekly cisplatin 40mg/m2 followed by one application of LDR 
brachytherapy 30 Gy to point A then parametrial boost 10-
15Gy/5Fr/1week. The patients were replanned with WP-IMRT. The 
margin was compatible with literatures and organ motion. DVHs were 
compared for the target volumes and OAS using paired t-test. 
Results: the mean target volume coverage by 95% (V42.7) was 95.78% 
for WP-3D-CRT and 93.22% for WP-IMRT (p value <0.001). IMRT was 
associated with significant dose reduction to OAS at V40 and V45 
levels. There was >20% reduction at V40 level for most of patients: 
63.52% (bladder), 16.67% (small bowel) and 37.12% (rectum). 
Conclusions: An initial IMRT plan with appropriate margin 
encompassing the target volumes and potential microscopic pelvic 
spread leads to reduction in the doses to OAS without compromising 
the target volume. while in locally advanced cases stage IIIB-IVA, 
there was a little benefit especially when large part of rectum or 
bladder were included in the target volumes.  
 
 POSTER: RTT TRACK: VOLUME DEFINITION, 
TREATMENT MARGINS, GEOMETRIC UNCERTAINTIES 
AND TREATMENT ACCURACY  
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Purpose/Objective: Radiotherapy quality assurance (RTQA) is now a 
requirement of radiotherapy trials since poor protocol compliance has 
been shown to impact on outcomes. We aim to determine the degree 
of variation in head and neck target contouring and the impact of 
RTQA feedback on clinician conformity using pre-accrual benchmark 
cases. 
Materials and Methods: Two trials, the first a randomised study of 
dose escalated intensity modulated radiotherapy (IMRT) verses 
standard dose IMRT in patients receiving treatment for locally 
advanced laryngeal / hypopharyngeal cancers (ART-DECO)and the 
second a study of cochlear-sparing IMRT versus conventional 
radiotherapy in patients with parotid tumours(COSTAR), require all 
prospective investigators to submit pre-accrual contouring benchmark 
cases. Cases are assessed for protocol compliance and resubmissions 
requested until trial compliant. All benchmark cases for ART-DECO 
and COSTAR until June 2012 arecollected in DICOM format. Cases were 
analysed using a tumour management group (TMG) consensus contour. 
Dice coefficient (DC), Jaccard index (JI) and geographical miss index 
(GMI) were calculated for each individual structure. The data was pre-
processed to ensure uniform structure nomenclature and then 
analysed using automated trial analysis tools built using MATLAB 
R2011a and CERR v.4.0.  
Results: By June 2012, 14 clinicians had submitted a total of 77 
exercises for the ART-DECO trial; 38 for case 1 and 39 for case 2. The 
maximum number of re-submissions was 4. For the COSTAR trial, 27 
clinicians had submitted a total of 53 benchmark cases.The maximum 
number of re-submissions was 3. A total of 700 target volume contours 
were analysed; 385 for ART-DECO (CTV1, spinal cord (SC), brainstem 
(BS), ipsilateral parotid (IP) and contralateral parotid (CP)) and 330 
for COSTAR (CTV1, SC, BS, CP, left cochlea and right cochlea). All 
conformity indices showed varying levels of conformity in clinician 
contouring. For ART-DECO exercise 1, BS had a median JI of 0.55 
(Interquartile Range (IQR) 0.11) and CTV1 had a median JI of 0.63 (IQR 
0.11). Improvements in JI were seen after each successive submission 
from individual clinicians. After submission 4 for ART-DECO exercise 1 
